557 related articles for article (PubMed ID: 18412164)
1. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
Wingard JB; Anderson B; Weissman D
Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
[TBL] [Abstract][Full Text] [Related]
2. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
4. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
Breckpot K; Dullaers M; Bonehill A; van Meirvenne S; Heirman C; de Greef C; van der Bruggen P; Thielemans K
J Gene Med; 2003 Aug; 5(8):654-67. PubMed ID: 12898635
[TBL] [Abstract][Full Text] [Related]
5. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
[TBL] [Abstract][Full Text] [Related]
6. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
[TBL] [Abstract][Full Text] [Related]
7. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
8. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
9. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
Li W; Li S; Hu Y; Tang B; Cui L; He W
Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
[TBL] [Abstract][Full Text] [Related]
10. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.
Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z
Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
13. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
Dullaers M; Thielemans K
J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
[TBL] [Abstract][Full Text] [Related]
14. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
15. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
16. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells.
Chen X; He J; Chang LJ
Retrovirology; 2004 Nov; 1():37. PubMed ID: 15518595
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
18. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.
BrĂ¥ve A; Ljungberg K; Boberg A; Rollman E; Isaguliants M; Lundgren B; Blomberg P; Hinkula J; Wahren B
Mol Ther; 2005 Dec; 12(6):1197-205. PubMed ID: 16112909
[TBL] [Abstract][Full Text] [Related]
19. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins.
Bazhan SI; Karpenko LI; Lebedev LR; Uzhachenko RV; Belavin PA; Eroshkin AM; Ilyichev AA
Mol Immunol; 2008 Feb; 45(3):661-9. PubMed ID: 17869341
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]